Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.33 |
| ▸ | PGR | P06401 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111930 | 0.76 | TRPA1 (0.42) | TRPA1NR3C1PGRARNR3C2 | |
| SCHEMBL11662994 | 0.74 | TRPA1 (0.45) | TRPA1NR3C1PGRARNR3C2 | |
| SCHEMBL22462367 | 0.73 | — | — | |
| SCHEMBL22771105 | 0.73 | — | — | |
| SCHEMBL25137147 | 0.71 | CA1 (0.39) | CYP3A4 | |
| SCHEMBL4254045 | 0.71 | CA1 (0.39) | CYP3A4 | |
| SCHEMBL4104417 | 0.70 | PTPN1 (0.54) | CYP3A4CYP2C9CYP2C19PTPN2PTPN1 | |
| SCHEMBL11501603 | 0.70 | NR3C1 (0.45) | TRPA1NR3C1PGRARNR3C2 | |
| SCHEMBL9386032 | 0.70 | PTPN2 (0.40) | TRPA1NR3C1PGRARNR3C2 | |
| SCHEMBL13950644 | 0.70 | TRPA1 (0.41) | TRPA1NR3C1PGRARNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197510-A1 | DELIVERY SYSTEMS COMPRISING MALODOR REDUCTION COMPOSITIONS | The Procter & Gamble Company (US) | 2017-08-02 | — | — | EP | claimed |
| EP-3197507-A1 | MALODOR REDUCTION COMPOSITIONS | The Procter and Gamble Company (US) | 2017-08-02 | — | — | EP | claimed |
| WO-2016049389-A1 | MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016049458-A1 | DELIVERY SYSTEMS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| EP-2430140-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132531-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-11-18 | — | — | WO | claimed |
| US-20230093639-A1 | PERFUME SYSTEM FOR PERFUMED CONSUMER PRODUCT | FIRMENICH SA (CH) | 2023-03-23 | — | — | US | disclosed |
| CN-103687847-B | The manufacturing method of isocyanate compound | 宇部兴产株式会社 | 2019-04-02 | — | — | CN | disclosed |
| US-20170137753-A1 | DELIVERY SYSTEMS COMPRISING MALODOR REDUCTION COMPOSITIONS | PROCTER & GAMBLE (US) | 2017-05-18 | — | — | US | disclosed |
| US-20100287710-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-11-18 | — | — | US | disclosed |
| US-20090076136-A1 | THERAPEUTIC AGENT | ENOKI TATSUJI | 2009-03-19 | — | — | US | disclosed |
| US-20070060641-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1627632-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-4179468-A | Cyclic terpenoid onium salts, their preparation and uses | SCM CORPORATION (US) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076136-A1 | THERAPEUTIC AGENT | GPR119, IAPP, FABP4 | TRPA1 3423/4885NR3C1 978/4885PGR 2855/4885 |
| US-20070060641-A1 | Therapeutic agent | GPR119, IAPP, FABP4 | TRPA1 3423/4885NR3C1 978/4885PGR 2855/4885 |
| US-20230093639-A1 | PERFUME SYSTEM FOR PERFUMED CONSUMER PRODUCT | PORCN, FAAH2, FASN | TRPA1 119/4885NR3C1 4624/4885PGR 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.